NIKKEI 225
38,314.94 +762.78 (+2.03%) HANG SENG
16,985.37 +156.44 (+0.93%) CRUDE OIL
83.33 -0.03 (-0.04%) GOLD FUTURES
2,329.70 -12.40 (-0.53%) DOW
38,503.69 +263.71 (+0.69%) Bitcoin GBP
53,527.32 -177.54 (-0.33%)
Oxford BioMedica plc (OXB.L)
| Previous close | 212.50 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 309,696 |
| Market cap | 215M |
| Beta (5Y monthly) | 1.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.64 |
| Earnings date | 29 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 419.63 |
Simply Wall St.Oxford Biomedica Insiders Placed Bullish Bets Worth UK£415.3k
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Globe NewswireUpdate to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024 revenue range of £126 million to £134 million, reflecting the successful integration of ABL Europe and anticipated growth from new and existing client programmesFY2023 revenues and EBITDA expected to be in line with guidance provided at the Interim ResultsFY2023 Preliminary Results to be reported on
GlobeNewswireOxford Biomedica completes acquisition of ABL Europe
Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UKExpands Oxford Biomedica’s ability to serve more clients, unlocking development capacity and increasing revenues3.2 per cent of the Company’s share capital issued to Institut Mérieux at a share price of 407.4p Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Bio
